Tag: congress

苏格兰格拉斯哥, June 09, 2026 (GLOBE NEWSWIRE) -- 万益特（Vantive），作为一家拥有70年肾脏护理创新历史的重要脏器疗法公司，今日发布两项突破性临床研究：采用 泰诺佳^® 透析器的 HDx 疗法，与在线血液透析滤过（OL-HDF）相比，在全因死亡率和主要心血管结局方面*表现相似（统计学上非劣效）。^1,2随机对照试验MOTheR 研究、真实世界研究CONCORDIA中期数据，已于 2026 年 6 月 3–6 日在苏格兰格拉斯哥举办的第 63届欧洲肾脏协会（ERA）大会上发布。

Châtillon, France, June 8, 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido^®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978